What is the efficacy of sodium-glucose cotransporter 2 (SGLT2) inhibitors for the treatment of chronic gout?

Updated: Jan 26, 2021
  • Author: Bruce M Rothschild, MD; Chief Editor: Herbert S Diamond, MD  more...
  • Print

Fralick et al reported that in patients with type 2 diabetes mellitus who were treated with sodium-glucose cotransporter 2 (SGLT2) inhibitors, which prevent the reabsorption of glucose and lower serum uric acid levels, the incidence of gout was approximately 40% lower than in patients treated with glucagonlike peptide–1 receptor (GLP-1) agonists. Their population-based study, in 295,907 adults with type 2 diabetes mellitus, found that the gout incidence rate in patients who were newly prescribed an SGLT2 inhibitor was 4.9 events per 1000 person-years, compared with 7.8 events per 1000 person-years in those newly prescribed a GLP-1 agonist (hazard ratio 0.64, 95% confidence index [CI], 0.57 to 0.72; rate difference per 1000 person-years, −2.9, 95% CI −3.6 to −2.1). [154]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!